Stryker Co. (NYSE:SYK) Shares Sold by Impax Asset Management Group plc

Impax Asset Management Group plc reduced its holdings in Stryker Co. (NYSE:SYK) by 3.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,622 shares of the medical technology company’s stock after selling 243 shares during the period. Impax Asset Management Group plc’s holdings in Stryker were worth $2,392,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Quintet Private Bank Europe S.A. grew its stake in Stryker by 24.4% in the 3rd quarter. Quintet Private Bank Europe S.A. now owns 7,230 shares of the medical technology company’s stock valued at $2,612,000 after acquiring an additional 1,418 shares during the period. PDS Planning Inc lifted its holdings in Stryker by 5.5% during the third quarter. PDS Planning Inc now owns 1,422 shares of the medical technology company’s stock valued at $514,000 after purchasing an additional 74 shares in the last quarter. QRG Capital Management Inc. grew its position in shares of Stryker by 4.8% in the third quarter. QRG Capital Management Inc. now owns 61,249 shares of the medical technology company’s stock valued at $22,127,000 after purchasing an additional 2,822 shares during the period. Asset Management One Co. Ltd. increased its stake in shares of Stryker by 2.7% during the third quarter. Asset Management One Co. Ltd. now owns 132,737 shares of the medical technology company’s stock worth $47,953,000 after purchasing an additional 3,438 shares in the last quarter. Finally, National Pension Service raised its position in shares of Stryker by 12.8% during the 3rd quarter. National Pension Service now owns 733,536 shares of the medical technology company’s stock worth $264,997,000 after purchasing an additional 83,362 shares during the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on SYK shares. StockNews.com upgraded Stryker from a “hold” rating to a “buy” rating in a report on Tuesday, October 1st. BTIG Research boosted their price target on Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Wolfe Research initiated coverage on Stryker in a research note on Tuesday, September 10th. They issued an “outperform” rating and a $405.00 price objective for the company. Piper Sandler reaffirmed an “overweight” rating and set a $420.00 target price (up previously from $380.00) on shares of Stryker in a research note on Wednesday, October 30th. Finally, Needham & Company LLC increased their target price on shares of Stryker from $393.00 to $409.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Four investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $393.65.

Stryker Price Performance

NYSE:SYK opened at $369.86 on Wednesday. Stryker Co. has a 52 week low of $266.93 and a 52 week high of $374.63. The stock’s fifty day moving average is $360.66 and its two-hundred day moving average is $344.95. The company has a market capitalization of $141.00 billion, a P/E ratio of 39.64, a P/E/G ratio of 2.77 and a beta of 0.91. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The firm had revenue of $5.49 billion for the quarter, compared to analyst estimates of $5.37 billion. During the same period in the previous year, the firm earned $2.46 EPS. Stryker’s revenue was up 11.9% on a year-over-year basis. Equities analysts expect that Stryker Co. will post 12.06 EPS for the current year.

Insider Transactions at Stryker

In other Stryker news, insider Viju Menon sold 600 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total value of $213,000.00. Following the sale, the insider now owns 9,069 shares of the company’s stock, valued at $3,219,495. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Stryker news, insider Viju Menon sold 600 shares of Stryker stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total value of $213,000.00. Following the completion of the transaction, the insider now directly owns 9,069 shares of the company’s stock, valued at $3,219,495. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP M Kathryn Fink sold 7,347 shares of the stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total transaction of $2,696,202.06. Following the sale, the vice president now directly owns 10,042 shares in the company, valued at $3,685,213.16. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 10,068 shares of company stock worth $3,693,972. 5.50% of the stock is currently owned by insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.